Skip to search boxSkip to navigationSkip to main content

Effect of rapamycin on cytokine profile in kidney transplant recipients treated with triple drug therapy

  • L. E. Morales-Buenrostro
    ,
  • L. Llorente
    ,
  • Y. Richaud-Patin
    ,
  • C. De Leo
    ,
  • ,
  • A. Diáz-Alderete
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Research Output:
Contribution to journal
Article
Peer-review

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 1661-1663 (3 pages)

Journal (Volume, Issue Number)

Transplantation Proceedings (Volume 36, Issue 6)

Publication milestones

  • Published - 01/07/2004

Publication status

Published - 01/07/2004

ISSN

0041-1345

Publication IDs

  • Scopus: 4444373657
  • PubMed: 15350444

Abstract

The aim of this study was to explore differences in the cytokine profile among de novo kidney transplant recipients treated with either Rapamycin (Rapa) + cyclosporine (CsA) + prednisone (P) or CsA + azathioprine (Aza) + P. Among the 13 adult kidney transplant recipients studied, seven received Rapa + CsA + P while the remaining six received CsA + Aza + P with their living donors serving as controls (n = 13). Spontaneous production of IL-2, IFNγ, IL-10, and TGF-β were measured by ELISA in supernatants from 24-hour cultured unstimulated peripheral blood mononuclear cell (PBMC) at time zero (the day before the transplant), and at 3 and 6 months posttransplant. Cytokines were also measured 1 month after CsA withdrawal in the Rapa + CsA + P group. From time zero to the end of the study, IL-2, IFNγ, and IL-10 were present at low or undetectable levels in all three groups. TGF-β tended to increase in supernatants from patients under Rapa + CsA + P at 6 months posttransplant and at 1 month after CsA withdrawal without correlation to Rapa blood levels. TGF-β remained stable throughout the study period for patients included in the CsA + Aza + P group. There was no difference in this cytokine level between these study groups at any given time. This study showed no differences in the spontaneous cytokine profiles evaluated in patients treated with both therapeutic schemes.